Efficacy of Whole System Approach of Ayurveda as an Add- on to Conventional Medicine in the Management of Clinical Phenotypes of Chronic Obstructive Pulmonary Disease(Tamaka Shwasa Roga)- A Single Blind Randomized Controlled Trial - NI

Institute of Teaching and Research in Ayurveda0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年9月18日

试验速览

暂无简介。

•1. Patients willing for trial and ready to give informed consent
•2. Patients who have symptomatic stable COPD diagnosis with postbronchodilator FEV1/FVC ratio <0.70
•3. Patients getting conventional treatment as per allopathic standards
•4. GOLD grade I, II and III

•1. Patients not willing for trial.
•2. Age more than 70 years or less than 40 years.
•3. Patients having bronchial asthma.
•4. Patients not getting conventional treatment as
•per allopathic standards.
•5. Patients who have a history of myocardial infarction, heart failure, acute ischemic coronary disease or severe cardiac arrhythmia requiring treatment within the last 6 weeks
•6. Patients with concomitant pulmonary disease, e.g., pulmonary tuberculosis or clinically significant bronchiectasis, sarcoidosis and interstitial lung disorder.
•7. Patients with advanced Type II respiratory failure, GOLD grade IV (FEV1% <30% of predicted).
•8. Patients requiring long-term oxygen therapy (LTOT).
•9. Patients suffering from major systemic illness necessitating long-term treatment (R.A., malignancy).
•10. Poorly controlled hypertensive (BP >180/100 mm of Hg) and diabetic patients (FBS >150mg/dl)
•11. Patients having end-stage hepatic dysfunction (AST/ALT > 4 times of upper standard limit), or renal dysfunction (S.creatinine >1.2mg/dl).
•12. Patients who are found clinically unfit for Dosha and Bala-specific procedures.

发起方

Institute of Teaching and Research in Ayurveda